Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

Benzinga · May 8 08:12

Findings demonstrate ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-target edits detected

IND for PM359 recently cleared by U.S. FDA; data support advancement into Phase 1/2 clinical trial

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therapies, today reported new preclinical data demonstrating the ability of itsex vivo Prime Editing program, PM359, to correct a common disease-causing mutation of chronic granulomatous disease (CGD). The data will be...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Prime Medicine Presents Preclinical Data Demonstrating Ability Of PM359 To Efficiently, Reproducibly And Durably Correct Causative Mutation Of Chronic Granulomatous Disease

Risk Disclaimer